Onderneming Xenetic Biosciences Inc Nasdaq
Aandelen
US9840152063
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Cell-based Therapeutics
100,0
%
| 2 | 100,0 % | 3 | 100,0 % | +48,80% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 2 | 100,0 % | 3 | 100,0 % | +48,80% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 11-07-16 | |
James Parslow
DFI | Director of Finance/CFO | 59 | 03-04-17 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 01-03-14 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 11-07-16 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 14-08-17 |
Dmitriy Genkin
BRD | Director/Board Member | 56 | 01-01-04 |
Roger Kornberg
BRD | Director/Board Member | 77 | 29-02-16 |
Director/Board Member | 72 | 23-01-14 | |
Director/Board Member | 54 | 19-07-19 | |
James Callaway
BRD | Director/Board Member | 68 | 14-08-17 |
Director/Board Member | 55 | 25-09-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 1 804 394 | 0 | 0 | 80,81 % |
Aandeel B | 1 | 1 543 385 | 1 247 242 ( 80,81 %) | 2 701 ( 0,1750 %) | |
Aandeel C | 0 | 970 000 | 0 | 0 |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,58% | 115 mld. | |
+12,41% | 106 mld. | |
-2,59% | 21,96 mld. | |
-12,38% | 21,87 mld. | |
-5,29% | 19,21 mld. | |
-3,35% | 18,08 mld. | |
-38,57% | 17,71 mld. | |
+7,51% | 14,32 mld. | |
+35,67% | 12,42 mld. |